Skip to main content

VCYT Veracyte, Inc.

Healthcare

24.33 USD 1D -0.30 -1.22% Close 11/13
Since 2024-12-13 -43.0%

Close 11/13

Open
24.49
High
24.65
Low
23.45
Prev close
24.63
Volume
2.03M
Amplitude
4.87%
P/E
16.0
P/B
1.4
Revenue YoY (TTM)
+17.5%
52W 21.91 60.91
FinLab Studio

From Veracyte, Inc. to every stock like it

AI finds several complementary traits of Veracyte, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Veracyte, Inc.

Is Veracyte, Inc. a buy? Fundamentals and valuation first

As of 2026-11-12

Valuation: Fair, Quality: Good, Growth: Strong; Momentum: Weak.

Valuation Fair Free-cash-flow yield is Good; Price / book is Fair.
TTM P/E 16.0 44th percentile · Fair
Price / book 1.4 47th percentile · Fair
Free-cash-flow yield (%) 8.1 77th percentile · Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Good FCF margin, TTM is Top; ROE, TTM is Good.
ROE, TTM (%) 8.9 62th percentile · Good
Operating margin, TTM (%) 15.4 65th percentile · Good
FCF margin, TTM (%) 27.7 84th percentile · Top
Quality Factor Investing: A US Quality Value Backtest
Growth Strong Diluted EPS growth, TTM YoY is Top; Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 17.5 71th percentile · Good
Diluted EPS growth, TTM YoY (%) 310.1 92th percentile · Top
Momentum Weak All 2 indicators are Lagging.
60-day return (%) -41.6 13th percentile · Lagging
240-day return (%) -48.0 20th percentile · Lagging
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Lagging.
20-day dollar volume 86,497,912.0 85th percentile · Top
60-day annualized volatility (%) 125.9 87th percentile · Lagging
Factor Investing Explained: 10 Classic Factors in US Stocks

Veracyte, Inc. (VCYT) today

2 quant signals active · As of 2026-11-12

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

Veracyte, Inc. (VCYT) peers and tracking

Watchlist

This page refreshes daily after the close. Add Veracyte, Inc. to your watchlist to track signal changes on your next visit.

Veracyte, Inc. (VCYT) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 17.5%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

16 historical occurrences (since 2018-05-01)

Average forward return after Filed revenue acceleration

20-day: Win 66.7%, Sample 15, Median +10.1%, Excess +6.0%, Beat mkt rate 60.0%

60-day: Win 73.3%, Sample 15, Median +15.0%, Excess +11.1%, Beat mkt rate 73.3%

120-day: Win 57.1%, Sample 14, Median +15.0%, Excess +18.0%, Beat mkt rate 57.1%

120 days after: historical avg +19.8%

20-day +7.1%
60-day +12.3%
120-day +19.8%
20-day
60-day
120-day
Win
66.7%
73.3%
57.1%
Sample
15
15
14
Median
+10.1%
+15.0%
+15.0%
Excess
+6.0%
+11.1%
+18.0%
Beat mkt rate
60.0%
73.3%
57.1%

Over 14 occurrences, 120-day forward avg gained 19.8%, beat the market by 18.0 pts; win rate 57.1%.

EPS surprise beat

Active · now 24.3%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
33 historical occurrences (since 2016-03-10)

Average forward return after EPS surprise beat

20-day: Win 56.2%, Sample 32, Median +5.0%, Excess +6.2%, Beat mkt rate 56.2%

60-day: Win 68.8%, Sample 32, Median +10.3%, Excess +7.2%, Beat mkt rate 59.4%

120-day: Win 58.1%, Sample 31, Median +4.7%, Excess +7.6%, Beat mkt rate 45.2%

120 days after: historical avg +14.3%

20-day +7.7%
60-day +11.3%
120-day +14.3%
20-day
60-day
120-day
Win
56.2%
68.8%
58.1%
Sample
32
32
31
Median
+5.0%
+10.3%
+4.7%
Excess
+6.2%
+7.2%
+7.6%
Beat mkt rate
56.2%
59.4%
45.2%

Over 31 occurrences, 120-day forward avg gained 14.3%, beat the market by 7.6 pts; win rate 58.1%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 101,251 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.30%, a 58.3% positive-return rate, and +2.97 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

18 times historically; 60-day forward avg +15.0%, win rate 61.1%, beating the market by +10.8 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

20 times historically; 60-day forward avg +3.4%, win rate 63.2%, beating the market by -2.0 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.